SCHEMBL25868157

SCHEMBL25868157

CC(C)COCCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 1/20 0.32
PKM P14618 1/20 0.32
MEN1 O00255 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
NFKB1 P19838 1/20 0.32
PTGS1 P23219 1/20 0.32
APEX1 P27695 1/20 0.32
THPO P40225 1/20 0.32
PMP22 Q01453 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CTSV O60911 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25868159 0.97 POLB (0.34) POLBLMNATSHRALDH1A1PKM
SCHEMBL25891279 0.94 POLB (0.33) POLBLMNATSHRALDH1A1PKM
SCHEMBL17920552 0.89 MGLL (0.39) POLBLMNATSHRALDH1A1PKM
SCHEMBL17190593 0.87 LMNA (0.39) POLBLMNATSHRALDH1A1PKM
SCHEMBL25083956 0.86 POLB (0.36) POLBLMNATSHRALDH1A1PKM
SCHEMBL4741521 0.85 LMNA (0.38) POLBLMNATSHRALDH1A1PKM
SCHEMBL25892775 0.84 MGLL (0.35) POLBLMNATSHRALDH1A1PKM
SCHEMBL25083968 0.83 LMNA (0.33) LMNATSHRMEN1CYP3A4CYP2C9
SCHEMBL25084071 0.82 POLB (0.34) POLBLMNATSHRALDH1A1PKM
SCHEMBL17921780 0.82 POLB (0.34) POLBLMNATSHRALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A POLB 4149/4885LMNA 3307/4885TSHR 665/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R POLB 4542/4885LMNA 2973/4885TSHR 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.